The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study
The combination of PD-1 inhibitors and chemotherapy appears promising for locally advanced ESCC. Evaluating the differentiation status and dynamic changes of peripheral blood immune cells may provide valuable predictive insights into treatment efficacy and prognosis.
Authors
- Bowen Hu (ORCID: https://orcid.org/0000-0002-0966-9339)
- Feng Jiang (ORCID: https://orcid.org/0000-0001-6569-5956)
- Shaodi Wen (ORCID: https://orcid.org/0000-0001-7951-0123)
- Xinyu Xu (ORCID: https://orcid.org/0000-0002-1730-1462)
- Ruotong Wang (ORCID: https://orcid.org/0000-0002-0485-6848)
- Yihan Zhang (ORCID: https://orcid.org/0009-0009-1515-3257)
- Bo Shen (ORCID: https://orcid.org/0000-0001-9708-6098)
- Guoren Zhou (ORCID: https://orcid.org/0000-0002-8084-2800)
- Xiaomin Lu (ORCID: https://orcid.org/0009-0009-5491-3335)
- Xiaoyue Du
- Miaolin Zhu
- Jingwei Xia
Institutions
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
- Huaian First People’s Hospital (CN)
- Jiangsu Cancer Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/cam4.70228
- Citations
- 5
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Jiangsu Hengrui Medicine
- National Natural Science Foundation of China